| 臺大學術典藏 |
2020-05-20T05:11:42Z |
Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations
|
Yu C.-J.;Yang J.C.-H.;Shih J.-Y.;Lin Z.-Z.;Lee J.-H.;Chen K.-Y.;Yang C.-Y.;Hsu C.-L.;Ho C.-C.;Liao W.-Y.;Chen J.-S.;YEN-TING LIN; YEN-TING LIN; Chen J.-S.; Liao W.-Y.; Ho C.-C.; Hsu C.-L.; Yang C.-Y.; Chen K.-Y.; Lee J.-H.; Lin Z.-Z.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2020-05-25T01:32:58Z |
Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations
|
YEN-TING LIN; Chen J.-S.; Liao W.-Y.; Ho C.-C.; Hsu C.-L.; Yang C.-Y.; Chen K.-Y.; Lee J.-H.; Lin Z.-Z.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2020-07-21T06:46:16Z |
Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations
|
Lin Y.-T.; Chen J.-S.; Liao W.-Y.; CHAO-CHI HO; Hsu C.-L.; Yang C.-Y.; Chen K.-Y.; Lee J.-H.; Lin Z.-Z.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2020-08-13T06:33:27Z |
Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations
|
Yang J.C.-H.; Yu C.-J.; JIN-YUAN SHIH; Lin Z.-Z.; Lin Y.-T.; Chen J.-S.; Liao W.-Y.; Ho C.-C.; Hsu C.-L.; Yang C.-Y.; Chen K.-Y.; Lee J.-H. |
| 臺大學術典藏 |
2020-12-24T03:18:47Z |
Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations
|
Lin Y.-T.;Chen J.-S.;Liao W.-Y.;Ho C.-C.;Chia-Lin Hsu;Yang C.-Y.;Chen K.-Y.;Lee J.-H.;Lin Z.-Z.;Shih J.-Y.;Yang J.C.-H.;Yu C.-J.; Lin Y.-T.; Chen J.-S.; Liao W.-Y.; Ho C.-C.; CHIA-LIN HSU; Yang C.-Y.; Chen K.-Y.; Lee J.-H.; Lin Z.-Z.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2021-07-13T06:04:31Z |
Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations
|
Lin Y.-T.; Chen J.-S.; Liao W.-Y.; Ho C.-C.; Hsu C.-L.; Yang C.-Y.; Chen K.-Y.; LEE JIH-HSIANG; Lin Z.-Z.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2021-04-29T05:08:51Z |
Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations
|
Lin Y.-T.;Chen J.-S.;Liao W.-Y.;Ho C.-C.;Hsu C.-L.;Yang C.-Y.;Kuan-Yu Chen;Lee J.-H.;Lin Z.-Z.;Shih J.-Y.;Yang J.C.-H.;Yu C.-J.; Lin Y.-T.; Chen J.-S.; Liao W.-Y.; Ho C.-C.; Hsu C.-L.; Yang C.-Y.; KUAN-YU CHEN; Lee J.-H.; Lin Z.-Z.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2021-08-11T03:46:37Z |
Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations
|
Lin Y.-T.; Chen J.-S.; Liao W.-Y.; Ho C.-C.; Hsu C.-L.; Yang C.-Y.; Chen K.-Y.; Lee J.-H.; ZHONG-ZHE LIN; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2022-06-10T06:10:58Z |
Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations
|
Lin Y.-T.; Chen J.-S.; Liao W.-Y.; Ho C.-C.; Hsu C.-L.; Yang C.-Y.; Chen K.-Y.; Lee J.-H.; ZHONG-ZHE LIN; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2022-06-27T06:59:53Z |
Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations
|
Lin Y.-T.; Chen J.-S.; Liao W.-Y.; Ho C.-C.; Hsu C.-L.; Yang C.-Y.; Chen K.-Y.; Lee J.-H.; Lin Z.-Z.; Shih J.-Y.; Yang J.C.-H.; CHONG-JEN YU |
| 臺大學術典藏 |
2020 |
Clinical outcomes and toxicity predictors of thoracic re-irradiation for locoregionally recurrent lung cancer
|
Kuo S.-H.; Cheng A.-L; Yang J.C.-H; Lu S.-H; Lin Z.-Z; Yu C.-J; Yang W.-C; Feng-Ming Hsu; Chen Y.-H; Shih J.-Y |
| 臺大學術典藏 |
2020 |
Clinical outcomes and toxicity predictors of thoracic re-irradiation for locoregionally recurrent lung cancer
|
Yang W.-C.;Hsu F.-M.;Chen Y.-H.;Shih J.-Y.;Chong-Jen Yu;Lin Z.-Z.;Lu S.-H.;Yang J.C.-H.;Cheng A.-L.;Kuo S.-H.; Yang W.-C.; Hsu F.-M.; Chen Y.-H.; Shih J.-Y.; CHONG-JEN YU; Lin Z.-Z.; Lu S.-H.; Yang J.C.-H.; Cheng A.-L.; Kuo S.-H. |
| 臺大學術典藏 |
2020 |
Clinical outcomes and toxicity predictors of thoracic re-irradiation for locoregionally recurrent lung cancer
|
Kuo S.-H.; Cheng A.-L.; Yang J.C.-H.; Lu S.-H.; Lin Z.-Z.; Yu C.-J.; JIN-YUAN SHIH; Chen Y.-H.; Hsu F.-M.; Yang W.-C.; Yang W.-C.;Hsu F.-M.;Chen Y.-H.;Jin-Yuan Shih;Yu C.-J.;Lin Z.-Z.;Lu S.-H.;Yang J.C.-H.;Cheng A.-L.;Kuo S.-H. |
| 臺大學術典藏 |
2021-02-23T08:26:10Z |
Clinical outcomes and toxicity predictors of thoracic re-irradiation for locoregionally recurrent lung cancer
|
Yang W.-C.;Hsu F.-M.;Chen Y.-H.;Shih J.-Y.;Yu C.-J.;Lin Z.-Z.;Lu S.-H.;Yang J.C.-H.;Cheng A.-L.;Sung-Hsin Kuo; Yang W.-C.; Hsu F.-M.; Chen Y.-H.; Shih J.-Y.; Yu C.-J.; Lin Z.-Z.; Lu S.-H.; Yang J.C.-H.; Cheng A.-L.; SUNG-HSIN KUO |
| 臺大學術典藏 |
2021-04-23T05:56:29Z |
Clinical outcomes and toxicity predictors of thoracic re-irradiation for locoregionally recurrent lung cancer
|
Yang W.-C.;Hsu F.-M.;Chen Y.-H.;Shih J.-Y.;Yu C.-J.;Lin Z.-Z.;Lu S.-H.;Chih-Hsin Yang;Cheng A.-L.;Kuo S.-H.; Yang W.-C.; Hsu F.-M.; Chen Y.-H.; Shih J.-Y.; Yu C.-J.; Lin Z.-Z.; Lu S.-H.; CHIH-HSIN YANG; Cheng A.-L.; Kuo S.-H. |
| 臺大學術典藏 |
2021-07-02T03:21:35Z |
Clinical outcomes and toxicity predictors of thoracic re-irradiation for locoregionally recurrent lung cancer
|
WEN-CHI YANG; Hsu F.-M.; Chen Y.-H.; Shih J.-Y.; Yu C.-J.; Lin Z.-Z.; Lu S.-H.; Yang J.C.-H.; Cheng A.-L.; Kuo S.-H. |
| 臺大學術典藏 |
2021-08-11T03:46:34Z |
Clinical outcomes and toxicity predictors of thoracic re-irradiation for locoregionally recurrent lung cancer
|
Yang W.-C.; Hsu F.-M.; Chen Y.-H.; Shih J.-Y.; Yu C.-J.; ZHONG-ZHE LIN; Lu S.-H.; Yang J.C.-H.; Cheng A.-L.; Kuo S.-H. |
| 臺大學術典藏 |
2021-08-31T06:29:18Z |
Clinical outcomes and toxicity predictors of thoracic re-irradiation for locoregionally recurrent lung cancer
|
Yang W.-C.; Hsu F.-M.; Chen Y.-H.; Shih J.-Y.; Yu C.-J.; Lin Z.-Z.; Lu S.-H.; Yang J.C.-H.; ANN-LII CHENG; Kuo S.-H. |
| 臺大學術典藏 |
2022-06-10T06:10:55Z |
Clinical outcomes and toxicity predictors of thoracic re-irradiation for locoregionally recurrent lung cancer
|
Yang W.-C.; Hsu F.-M.; Chen Y.-H.; Shih J.-Y.; Yu C.-J.; ZHONG-ZHE LIN; Lu S.-H.; Yang J.C.-H.; Cheng A.-L.; Kuo S.-H. |
| 臺大學術典藏 |
2022-06-27T06:59:44Z |
Clinical outcomes and toxicity predictors of thoracic re-irradiation for locoregionally recurrent lung cancer
|
Yang W.-C.; Hsu F.-M.; Chen Y.-H.; Shih J.-Y.; CHONG-JEN YU; Lin Z.-Z.; Lu S.-H.; Yang J.C.-H.; Cheng A.-L.; Kuo S.-H. |
| 臺大學術典藏 |
2018-09-10T15:28:24Z |
Clinical Outcomes and Urodynamic Effects of Tailored Transvaginal Mesh Surgery for Pelvic Organ Prolapse
|
Chang, T.-C. and Hsiao, S.-M. and Chen, C.-H. and Wu, W.-Y. and Lin, H.-H.; HO-HSIUNG LIN; CHI-HAU CHEN |
| 臺大學術典藏 |
2020-01-22T08:53:05Z |
Clinical Outcomes and Urodynamic Effects of Tailored Transvaginal Mesh Surgery for Pelvic Organ Prolapse
|
Chang T.-C.; Hsiao S.-M.; CHI-HAU CHEN; Wu W.-Y.; Lin H.-H. |
| 臺大學術典藏 |
2020-02-17T05:28:09Z |
Clinical Outcomes and Urodynamic Effects of Tailored Transvaginal Mesh Surgery for Pelvic Organ Prolapse
|
TING-CHEN CHANG; Hsiao S.-M; Chen C.-H; Wu W.-Y; Lin H.-H. |
| 臺大學術典藏 |
2020-02-17T08:50:54Z |
Clinical Outcomes and Urodynamic Effects of Tailored Transvaginal Mesh Surgery for Pelvic Organ Prolapse
|
Chang T.-C; Hsiao S.-M; Chen C.-H; Wu W.-Y; HO-HSIUNG LIN |
| 臺大學術典藏 |
2021-03-03T03:00:58Z |
Clinical Outcomes and Urodynamic Effects of Tailored Transvaginal Mesh Surgery for Pelvic Organ Prolapse
|
Chang T.-C.; Hsiao S.-M.; Chen C.-H.; Wu W.-Y.; HO-HSIUNG LIN |
